Andrew A. Lukowiak - 01 Aug 2023 Form 4 Insider Report for Talis Biomedical Corp

Role
President, Chief Scientific Officer
Signature
/s/ Rebecca Markovich, Attorney-in-fact for Andrew A. Lukowiak
Issuer symbol
TLIS on OTC
Transactions as of
01 Aug 2023
Net transactions value
$0
Form type
4
Filing time
02 Aug 2023, 08:18:33 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TLIS Stock option (right to buy) Award $0 +30,575 $0.000000 30,575 01 Aug 2023 Common Stock 30,575 $7.42 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date of August 1, 2023 and 1/48th of the shares underlying this option shall vest monthly thereafter over 36 months.